In contrast, neither the drugs currently used in NB treatment [14] nor JQ1 [15], which aims at reducing the expression level of MYCN, have demonstrated immunomodulatory functions in terms of induction of ligands for NK-cell-activating receptors. This evidence concerns the gene MYCN and neuroblastoma.